# The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients

> **NCT01355523** · PHASE2,PHASE3 · TERMINATED · sponsor: **Melissa Voigt Hansen** · enrollment: 54 (actual)

## Conditions studied

- Breast Cancer
- Depression

## Interventions

- **DRUG:** Melatonin (N-acetyl-5-methoxytryptamine)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01355523
- **Lead sponsor:** Melissa Voigt Hansen
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2011-07
- **Primary completion:** 2013-01
- **Final completion:** 2013-01
- **Target enrollment:** 54 (ACTUAL)
- **Why stopped:** Inclusion rate not as expected. Not financially possible to involve other centres.
- **Last updated:** 2014-05-06

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01355523

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01355523, "The Effect of Melatonin on Depression, Anxiety, Cognitive Function and Sleep Disturbances in Breast Cancer Patients". Retrieved via AI Analytics 2026-07-02 from https://api.ai-analytics.org/clinical/NCT01355523. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*